-
MLV: We're Reiterating A Buy On Halozyme
Wednesday, April 8, 2015 - 4:36pm | 418In a report published Wednesday, MLV & Co analysts maintained a Buy rating for Halozyme Therapeutics, Inc (NASDAQ: HALO), with a price target of $20. Following a meeting with the FDA in 1Q15, the company has now announced its plans to commence a global registration based Phase 3 pancreatic...
-
UPDATE: MLV & Co Initiates Coverage On Ultragenyx Pharmaceutical On Positive Outlook
Tuesday, March 31, 2015 - 7:47am | 145In a report published Tuesday, MLV & Co analyst Arlinda Lee initiated coverage on Ultragenyx Pharmaceutical, Inc. (NASDAQ: RARE) with a Buy rating and $79.00 price target. In the report, MLV & Co noted, "With four product candidates in the clinic for six debilitating and life-threatening...
-
UPDATE: MLV & Co Initiates Coverage On Flexion Therapeutics On Multiple Positive Factors
Tuesday, March 31, 2015 - 7:36am | 143In a report published Tuesday, MLV & Co analyst Ken Trbovich initiated coverage on Flexion Therapeutics, Inc. (NASDAQ: FLXN) with a Buy rating and $38.00 price target. In the report, MLV & Co noted, "Flexion's stock has performed well since its IPO last year, but we think it is far from...
-
MLV & Co Reiterates Buy, Lowers PT On Carrizo Oil & Gas On Equity Offering
Tuesday, March 24, 2015 - 7:03am | 143In a report published Tuesday, MLV & Co analyst Chad Mabry reiterated a Buy rating on Carrizo Oil & Gas, Inc. (NASDAQ: CRZO), but lowered the price target from $65.00 to $60.00. In the report, MLV & Co noted, "Sometimes it's best to raise capital when you can, not when you need to. That...
-
UPDATE: MLV & Co Initiates Coverage On Rexahn Pharmaceuticals On Oncology Pipeline With Strategic Flexibility
Friday, March 20, 2015 - 10:26am | 228In a report published Friday, MLV & Co analyst Vernon T. Bernardino initiated coverage on Rexahn Pharmaceuticals, Inc. (NYSE: RNN) with a Buy rating and $1.25 price target. In the report, MLV & Co noted, "We initiate coverage of Rexahn Pharmaceuticals Inc. (RNN) with a BUY rating and $1.25...
-
MLV & Co Sees Strong Beat And Positive 2015 Outlook For Summit Hotel Properties
Tuesday, March 3, 2015 - 10:38am | 150In a report published Tuesday, MLV & Co analyst Ryan Meliker reiterated a Buy rating and $15.00 price target on Summit Hotel Properties, Inc. (NYSE: INN). In the report, MLV & Co noted, "INN reported very strong 4Q results and issued 2015 RevPAR guidance above what we believe were already...
-
MLV & Co Upgrades Acura Pharmaceuticals To Buy
Friday, February 27, 2015 - 9:59am | 60Analysts MLV & Co upgraded Acura Pharmaceuticals, Inc. (NASDAQ: ACUR) from Hold to Buy. The price target for Acura Pharmaceuticals is set to $1. Acura Pharmaceuticals shares have dropped 61.62% over the past 52 weeks, while the S&P 500 index has surged 13.51% in the same period. Acura...
-
MLV & Co Believes Guidance Might Be Enough For RLJ Lodging Trust
Thursday, February 26, 2015 - 8:49am | 168In a report published Thursday, MLV & Co analyst Ryan Meliker reiterated a Buy rating and $39.00 price target on RLJ Lodging Trust (NYSE: RLJ). In the report, MLV & Co noted, "Given the recently lowered expectations for RLJ, with the stock down 5.4% YTD on concerns surrounding heavy...
-
MannKind's Accounting Is 'Murky,' MLV Analyst Says
Wednesday, February 25, 2015 - 11:15am | 331MLV & Co. commented on MannKind Corporation (NASDAQ: MNKD) following the company’s Q4 earnings report. The firm maintained a Hold rating and $7 price target. Analyst Arlinda Lee noted that the company reported in line results but looked for data on NRx and TRx for Afrezza, as well...
-
MLV & Co Reiterates Buy, Lowers Price Target On Strategic Hotels And Resorts Following 4Q Review
Wednesday, February 25, 2015 - 9:43am | 194In a report published Wednesday, MLV & Co analyst Ryan Meliker reiterated a Buy rating on Strategic Hotels and Resorts Inc. (NYSE: BEE), but lowered the price target from $16.00 to $15.00. In the report, MLV & Co noted, "BEE's 4Q print was relatively disappointing as EBITDA and FFO came in...
-
MLV & Co Sees No Major Surprises In Earnings Update For Carrizo Oil & Gas
Wednesday, February 25, 2015 - 8:59am | 114In a report published Wednesday, MLV & Co analyst Chad Mabry reiterated a Buy rating and $65.00 price target on Carrizo Oil & Gas, Inc. (NASDAQ: CRZO). In the report, MLV & Co noted, "No major surprises in the earnings update as the company had pre-reported most material datapoints at...
-
MLV & Co Reiterates Buy, Raises Price Target On PDC Energy Following Strong Earnings Print
Friday, February 20, 2015 - 11:03am | 132In a report published Friday, MLV & Co analyst Chad Mabry reiterated a Buy rating on PDC Energy Inc (NASDAQ: PDCE), and raised the price target from $62.00 to $66.00. In the report, MLV & Co noted, "Another strong earnings print reinforces what we already know: PDCE remains well-positioned...
-
Hatteras Financial PT Cut By MLV
Thursday, February 19, 2015 - 8:24pm | 255In a report published Thursday, MLV & Co analyst Richard Eckert maintained a Buy rating on Hatteras Financial (NYSE: HTS). The price target was reduced from $22.50 to $20.25. In the report, MLV & Co noted, "In part, the lower PT reflects a small decline in book value (BV) in 4Q14, but...
-
Negative Sentiment Towards Starwood Hotels & Resorts Worldwide May Be Turning Positive
Wednesday, February 11, 2015 - 11:40am | 218In a report published Wednesday, MLV & Co analyst Ryan Meliker reiterated a Buy rating and $91.00 price target on Starwood Hotels & Resorts Worldwide Inc (NYSE: HOT). In the report, MLV & Co noted, "HOT reported strong 4Q results, exceeding guidance and consensus expectations on both...
-
MLV & Co Reiterates Hold, Raises Price Target On Kimco Realty On Adjusted Estimates
Monday, February 9, 2015 - 9:04am | 85In a report published Monday, MLV & Co analyst Paul Morgan reiterated a Hold rating on Kimco Realty Corporation (NYSE: KIM), and raised the price target from $24.00 to $26.00. In the report, MLV & Co noted, "We are raising our PT to $26 (from $24) to reflect rolling forward our NAV per...